Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Bokor

Obstetrics & Gynecology Columbus, OH Medical Doctor

NPI 1477523454 CMS profile 339311

6100 E Main St, Suite 112, Columbus, OH 43213

Open in the dashboard

General payments

$35,080

141 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Bokor of Columbus, OH is reported in the CMS Open Payments database as having received $35,080 across 141 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,108 21
2024 General $5,045 22
2023 General $13,126 19
2022 General $5,462 21
2021 General $733 14
2020 General $1,751 25
2019 General $854 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Bokor
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Andrew Bokor were reported at $8,108. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Andrew Bokor Obstetrics & Gynecology median Middle half National median
2019 $854 $172 $62–$391 $163
2020 $1,751 $94 $36–$222 $114
2021 $733 $136 $42–$369 $132
2022 $5,462 $160 $50–$433 $149
2023 $13,126 $169 $56–$423 $160
2024 $5,045 $152 $50–$371 $164
2025 $8,108 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $28,803 27 payments
  2. Hologic, LLC $2,421 46 payments
  3. Vermillion, Inc. $1,513 23 payments
  4. Minerva Surgical, Inc $758 19 payments
  5. Abbott Laboratories $438 11 payments
  6. Acessa Health Inc. $309 1 payment
  7. Acessa Health Inc. $186 1 payment
  8. Gynesonics, Inc. $156 1 payment
  9. TherapeuticsMD, Inc. $122 2 payments
  10. Edwards Lifesciences Corporation $119 1 payment
  11. Other $255 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $24,000 6 payments
  2. Food and Beverage $6,972 127 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,000 3 payments
  4. Travel and Lodging $1,109 5 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $28,803 27 payments
  2. OVA1 $1,513 23 payments
  3. Novasure $786 19 payments
  4. ACESSA PROVU SYSTEM $591 9 payments
  5. Myosure $527 11 payments
  6. Fluent $487 9 payments
  7. ALINITY $438 11 payments
  8. Acessa $309 1 payment
  9. SONATA SONOGRAPHY-GUIDED TRANSCERVICAL FIBROID ABLATION SYSTEM $156 1 payment
  10. Omniscope $137 4 payments
  11. Other $721 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

150

Median for Obstetrics & Gynecology: 65

Drug cost

$9,555

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

44.7%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 83 $6,502
Valacyclovir Valacyclovir Hcl Brand 27 $1,043
Estradiol (Twice Weekly) Estradiol Brand 15 $1,027
Tolterodine Tartrate Er Tolterodine Tartrate Brand 12 $726
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 13 $256

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$16,475

Medicare's payments for the services billed

Medicare patients

88

Average age 72

Services billed

215

88 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 60%
Osteoporosis 42%
Depression 34%
Diabetes 24%
Ischemic heart disease 20%
Chronic kidney disease 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record